Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Madrigal Pharmaceuticals (MDGL) Long-Term Debt Issuances (2022 - 2023)

Madrigal Pharmaceuticals (MDGL) has disclosed Long-Term Debt Issuances for 4 consecutive years, with $15.0 million as the latest value for Q3 2023.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A to $15.0 million in Q3 2023 year-over-year; TTM through Jun 2024 was $15.0 million, a 70.0% decrease, with the full-year FY2025 number at $350.0 million, changed N/A from a year prior.
  • Long-Term Debt Issuances was $15.0 million for Q3 2023 at Madrigal Pharmaceuticals, roughly flat from $15.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $50.0 million in Q2 2022 to a low of $15.0 million in Q2 2023.